Former Celgene CEO Bob Hugin loses in US midterm elections

pharmafile | November 7, 2018 | News story | Research and Development Bob Hugin, Celgene, Trump, midterms, republican, us politics 

Former Celgene CEO Bob Hugin has failed in his bid to win over the people of New Jersey, after voters last night elected Democratic candidate Bob Menendez in the US midterm elections.

Despite receiving nearly three times as much in campaign finance, it was announced that the republican candidate lost the New Jersey Senate election, gaining 43.8% of the vote in comparison to his opponent Menendez’s 53.1% share.

While Hugin was the recipient of a total $30,289,561, Menendez received $11,631,183 in comparison. Hugin was reported by the Associated Press to have loaned his campaign $36 million.

Nevertheless, despite an onslaught of attack ads, Menendez won out. However Hugin did win with a significant majority in the Republican primaries beating fellow republican Brian Goldberg with 75.1% of the vote. The enthusiasm did not however translate to the final result.

Having begun his career at J.P Morgan the Union City, New Jersey native and Princeton alumnus went on to transform New Jersey-based Celgene increasing the company’s headcount from 200 to 6000 over his nearly two decade career.

In his race to senate the business guru was also the recipient of an endorsement from President Donald Trump who tweeted: “Bob Hugin, successful all of his life, would be a Great Senator from New Jersey. He has my complete and total Endorsement! Get out and Vote for Bob.”

Louis Goss

Related Content

Profits over patients: US pharma spending billions on investor payouts

In 2017 Donald Trump signed the Tax Cuts and Jobs Act (TCJA), creating billions of …


NICE recommends Celgene’s REVLIMID for multiple myeloma

NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …


US pharma lobby launches legal action against the Trump administration over drug pricing proposals

US industry organisations including the Pharmaceutical Research and Manufacturers of America (PhRMA) have launched legal …

Latest content